These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34521513)

  • 1. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience.
    Chilimuri S; Mantri N; Gurjar H; Youthjug KA; Sun H; Gongati S; Zahid M; Ronderos DM; De La Cruz A; Varanasi P; Shin D; Nayudu SK
    J Natl Med Assoc; 2022 Jan; 113(6):701-705. PubMed ID: 34521513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort.
    Nichols CN; Lustberg M; Sobhanie MME; Niermann LJ; Gordon M; Kman N; Parsons J; Conroy M; Dick M; Allen J; Reed E; Lehman J; Malvestutto C
    Antivir Ther; 2024 Aug; 29(4):13596535241264694. PubMed ID: 39066463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
    Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
    Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM
    J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
    Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
    Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real World Utilization of Bamlanivimab at a Rural Community Hospital.
    Leavitt R; Ash J; Hasenbalg P; Santarelli A; Dietrich T; Schritter S; Wells J; Dawson A; Ashurst J
    Cureus; 2021 Nov; 13(11):e19747. PubMed ID: 34938624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1-August 20, 2021): a retrospective observational monocentric study.
    Guo Y; Cowman K; Chang M; Bao H; Golia A; Mcsweeney T; Bard L; Simpson R; Andrews E; Pirofski LA; Nori P
    BMC Infect Dis; 2022 Jul; 22(1):645. PubMed ID: 35896965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
    Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
    J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
    Amanam I; Yao J; Puing A; Tsai NC; Samuels D; Ngo D; Ho S; Ali H; Aribi A; Arslan S; Artz A; Htut M; Koller P; Salhotra A; Sandhu K; Nikolaenko L; Pawlowska A; Shouse G; Stein A; Marcucci G; Forman S; Nakamura R; Dadwal S; Al Malki MM
    Cancer Med; 2023 May; 12(10):11248-11253. PubMed ID: 37081733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report.
    Pillai RLI; Dziel C; Vogel S; Szczerba F; Chang WW; Camelo IY; Paez A
    J Med Case Rep; 2023 Feb; 17(1):64. PubMed ID: 36823658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
    Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
    Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
    Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients.
    Milam AN; Doan DT; Childress DT; Durham SH
    J Pharm Technol; 2022 Jun; 38(3):169-173. PubMed ID: 35600282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19.
    Melton JD; Wilson K; Blind F; Barbera A; Bhisitkul D; Hasara S; Homa K; Karp J; Escowitz H; Haber T; DeGroot D; Anderson J; DeLeon J; Santos JL; Faviere D; Fuell J; Gillespie R; Glueck J; Reeber C; Rhodes DJ; Rodriguez V
    Am J Emerg Med; 2021 Dec; 50():437-441. PubMed ID: 34487951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].
    Lebedkina MS; Fomina DS; Mutovina ZY; Mаrkina UA; Bogomolov PO; Chulanov VP; Lysenko MA; Alexeeva EI
    Ter Arkh; 2023 Aug; 95(6):494-499. PubMed ID: 38158969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study.
    Sherman G; Lamb GS; Sharma TS; Lloyd EC; Nagel J; Dandam NN; Oliveira CR; Sheikha HS; Anosike BI; Lee P; Vora SB; Patel K; Sue PK; Rubbab B; Yarbrough AM; Ganapathi L; Nakamura MM
    J Pediatric Infect Dis Soc; 2023 Apr; 12(3):152-155. PubMed ID: 36928172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
    Razonable RR; Pawlowski C; O'Horo JC; Arndt LL; Arndt R; Bierle DM; Borgen MD; Hanson SN; Hedin MC; Lenehan P; Puranik A; Seville MT; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Ganesh R
    EClinicalMedicine; 2021 Oct; 40():101102. PubMed ID: 34485873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders.
    Franchin G; Mantri N; Zahid M; Sun H; Gongati SR; Ronderos DM; Gadireddy S; Chilimuri S
    Med Sci Monit; 2021 Nov; 27():e934267. PubMed ID: 34819488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital.
    Pannier J; Nass N; Yaakoub MK; Stelzner FMM; Veit S; Kalomoiri M; Yassine M; Behre G
    Infect Dis Rep; 2023 Feb; 15(1):125-131. PubMed ID: 36826353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.